Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.